HK Stock Market Move | CUTIA-B(02487) surged more than 3%. CU-20101 (injectable type A botulinum toxin) completed Phase III clinical trials in China.
Kodiv-B (02487) went up by more than 3%, as of the time of writing, it increased by 3.25% to 4.76 Hong Kong dollars, with a turnover of 409,900 Hong Kong dollars.
CUTIA-B (02487) rose more than 3%, as of the time of publication, it rose by 3.25% to HK$4.76, with a turnover of HK$409,900.
On the news front, Kedi announced today that the group has completed the phase III clinical trial of CU-20101 (botulinum toxin type A for injection) for improving moderate to severe glabellar lines in China. The clinical trial aims to evaluate the effectiveness and safety of single and repeated injections of CU-20101 in treating moderate to severe glabellar lines, with a comparator drug, BOTOX, used as a control. The clinical trial completed the exit of all subjects in November 2025 and locked the database in January 2026, with positive top-line results obtained.
Related Articles
HK Stock Market Move | Estun Automation (02715) rose more than 6%, expected to be included in the Hong Kong Stock Connect list soon, and is expected to achieve significant growth in its European business this year.
Defense application satellite assisted signal processing platform HawkEye 360 (HAWK.US) applies for IPO on the US stock market, aiming to raise up to $100 million.
GF SEC: The increase in electricity consumption boosts thermal power, and the electricity supply and demand pattern improves.
HK Stock Market Move | Estun Automation (02715) rose more than 6%, expected to be included in the Hong Kong Stock Connect list soon, and is expected to achieve significant growth in its European business this year.
Defense application satellite assisted signal processing platform HawkEye 360 (HAWK.US) applies for IPO on the US stock market, aiming to raise up to $100 million.
GF SEC: The increase in electricity consumption boosts thermal power, and the electricity supply and demand pattern improves.
RECOMMEND
